Instaryl Expectorant is a combination medication containing Terbutaline sulfate (2.5 mg/5 ml) and Bromhexine hydrochloride (8 mg/5 ml), formulated to provide effective relief from respiratory conditions characterized by excessive mucus production and bronchial obstruction. Terbutaline, a selective beta-2 adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby facilitating easier breathing and improving airflow in conditions such as bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). Bromhexine serves as a mucolytic agent, promoting the breakdown and clearance of viscous mucus by enhancing mucociliary transport and reducing sputum viscosity. The synergistic action of these two active ingredients aids in alleviating cough associated with productive respiratory tract disorders, facilitating expectoration, and reducing airway resistance. Instaryl Expectorant is indicated for symptomatic treatment of acute and chronic respiratory diseases where mucus hypersecretion and bronchospasm coexist. It is administered orally, with dosage adjusted according to patient age and severity of symptoms. Caution is advised in patients with cardiovascular disorders, hyperthyroidism, and diabetes. Common adverse effects may include tremors, palpitations, gastrointestinal discomfort, and hypersensitivity reactions. Use under medical supervision is recommended to ensure safety and efficacy.